title: [Importance of dyslipidaemia in cardiovascular disease: a point of view].
abstract: The authors present their view on the prevention of cardiovascular diseases, accepting the European ESC/EAS guidelines. They consider that the aim of the lipid control, based on LDL-C goals, is essential for the prevention and treatment of cardiovascular diseases. In subjects with metabolic syndrome (mainly, abdominal obesity, pre-diabetes and diabetes), the primary objective should be apoB or Non-HDL-C, which are better associated with cardiovascular risk. The treatment must be lifestyle changes and control of other risk factors. After calculating cardiovascular risk, statins are the first therapeutic step, with the strength and dose needed to achieve LDL-C goals. If targets are not achieved, ezetimibe or resins should be added. A new group of potent cholesterol-lowering agents, the PCSK-9 monoclonal antibodies, have recently been approved in Spain. Subjects at very high cardiovascular risk that have achieved LDL-C goals, or other objectives (apoB, Non-HDL-C), other drugs (fibrates, omega-3) capable of modifying triglycerides and HDL-C could be added, if necessary. Treatment to reduce cardiovascular risk and prevent cardiovascular disease has proven effective in all populations and at all age groups. Subjects older than 80years should be individually assessed, taking into consideration possible comorbidities.
authors.affiliation: Hospital Clínico Universitario, INCLIVA, CIBERDEM, Departamento de Medicina, Universitat de Valencia, Valencia, España; Presidente de la Sociedad Española de Arteriosclerosis, España. Electronic address: ascaso@uv.es.
authors.forename: Juan F
authors.initials: JF
authors.lastname: Ascaso
authors.affiliation: Hospital Clínico Universitario, INCLIVA, CIBERDEM, Departamento de Medicina, Universitat de Valencia, Valencia, España; exPresidente de la Sociedad Española de Arteriosclerosis, España.
authors.forename: Rafael
authors.initials: R
authors.lastname: Carmena
mesh_terms: D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D050171:Dyslipidemias / Q000150:complications / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D008019:Life Style; D008055:Lipids / Q000097:blood; D024821:Metabolic Syndrome / Q000150:complications / Q000628:therapy; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids
keywords: ApoB; Apolipoproteína B (ApoB); Cardiovascular risk; Colesterol no-HDL; LDL objectives; Management; Non-HDL-cholesterol; Objetivos LDL; Riesgo cardiovascular; Tratamiento